Kyverna Therapeutics, Inc.
KYTX
$7.66
-$0.19-2.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -19.66% | -320.09% | 4.33% | 31.09% | 66.55% |
| Gross Profit | 19.66% | 320.09% | -4.33% | -31.09% | -66.55% |
| SG&A Expenses | 13.22% | 22.63% | -13.65% | 40.56% | 72.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.74% | -4.29% | -0.11% | 32.82% | 67.77% |
| Operating Income | 12.74% | 4.29% | 0.11% | -32.82% | -67.77% |
| Income Before Tax | 10.99% | -0.84% | -6.65% | -46.10% | -67.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.99% | -0.84% | -6.65% | -46.10% | -67.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.99% | -0.84% | -6.65% | -46.10% | -67.22% |
| EBIT | 12.74% | 4.29% | 0.11% | -32.82% | -67.77% |
| EBITDA | 12.56% | -90.72% | -0.15% | -32.92% | -68.88% |
| EPS Basic | 36.35% | 7.55% | -6.02% | -45.76% | 8.09% |
| Normalized Basic EPS | 36.34% | 7.55% | -6.03% | -45.78% | 4.14% |
| EPS Diluted | 36.10% | 7.55% | -6.02% | -45.76% | 8.09% |
| Normalized Diluted EPS | 36.34% | 7.55% | -6.03% | -45.78% | 4.14% |
| Average Basic Shares Outstanding | 39.84% | 9.08% | 0.60% | 0.23% | 81.93% |
| Average Diluted Shares Outstanding | 39.84% | 9.08% | 0.60% | 0.23% | 81.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |